We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$531M
AUM Growth
-$19.6M
Cap. Flow
-$36.7M
Cap. Flow %
-6.9%
Top 10 Hldgs %
30.22%
Holding
139
New
9
Increased
20
Reduced
40
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.09M
2
SYK icon
Stryker
SYK
+$5.81M
3
AMSG
Amsurg Corp
AMSG
+$5.72M
4
ABMD
Abiomed Inc
ABMD
+$5.69M
5
HOLX
Hologic
HOLX
+$5.45M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$6.82M
2
BDX icon
Becton Dickinson
BDX
+$6.76M
3
BIIB icon
Biogen
BIIB
+$5.81M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$4.91M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.49M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHPG
26
DELISTED
Shire pic
SHPG
$7.15M 1.35%
38,850
+4,970
+15% +$897K
EW icon
27
Edwards Lifesciences
EW
$49.4B
$6.78M 1.28%
204,000
-15,000
-7% -$513K
ABMD
28
DELISTED
Abiomed Inc
ABMD
$6.25M 1.18%
+57,200
New +$5.69M
CI icon
29
Cigna
CI
$74.5B
$6.14M 1.16%
48,000
– –
JNJ icon
30
Johnson & Johnson
JNJ
$609B
$6.07M 1.14%
50,000
– –
BCR
31
DELISTED
CR Bard Inc.
BCR
$5.88M 1.11%
25,000
– –
ALXN
32
DELISTED
Alexion Pharmaceuticals
ALXN
$5.77M 1.09%
49,400
– –
AMSG
33
DELISTED
Amsurg Corp
AMSG
$5.74M 1.08%
+74,000
New +$5.72M
VRTX icon
34
Vertex Pharmaceuticals
VRTX
$123B
$5.68M 1.07%
66,000
– –
HUM icon
35
Humana
HUM
$48B
$5.4M 1.02%
30,000
– –
VTRS icon
36
Viatris
VTRS
$20.1B
$5.18M 0.97%
119,700
-100,300
-46% -$4.44M
CHRS icon
37
Coherus Oncology
CHRS
$216M
$5.13M 0.97%
304,000
+17,000
+6% +$319K
BMRN icon
38
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.06M 0.95%
65,000
– –
ESRX
39
DELISTED
Express Scripts Holding Company
ESRX
$4.93M 0.93%
65,000
+6,400
+11% +$471K
MCK icon
40
McKesson
MCK
$98.5B
$4.85M 0.91%
26,000
-17,000
-40% -$2.98M
MDVN
41
DELISTED
MEDIVATION, INC.
MDVN
$4.7M 0.88%
78,000
+15,000
+24% +$851K
STJ
42
DELISTED
St Jude Medical
STJ
$4.68M 0.88%
60,000
-62,000
-51% -$4.42M
COO icon
43
Cooper Companies
COO
$14B
$4.03M 0.76%
94,000
– –
PRGO icon
44
Perrigo
PRGO
$1.48B
$3.99M 0.75%
44,000
+11,400
+35% +$1.18M
MASI
45
DELISTED
Masimo
MASI
$3.94M 0.74%
75,000
– –
ARIA
46
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.66M 0.69%
495,000
– –
AKRX
47
DELISTED
Akorn Inc
AKRX
$3.62M 0.68%
+127,000
New +$3.52M
NUVA
48
DELISTED
NuVasive, Inc.
NUVA
$3.58M 0.67%
60,000
– –
CERN
49
DELISTED
Cerner Corp
CERN
$3.52M 0.66%
60,000
– –
HCA icon
50
HCA Healthcare
HCA
$82.3B
$3.37M 0.63%
43,700
-16,300
-27% -$1.29M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2016 Portfolio in Review

As of Q2 2016, Bellevue Group held 139 positions worth $531M, down 3.6% from $551M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group withdrew a net $36.7M in Q2 2016, closing 15 positions and reducing 40 holdings. Its most notable exit was Insys Therapeutics, Inc., an estimated $4.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Allergan plc worth $8.11M.

  • Bellevue Group's largest Q2 2016 buy was Allergan plc: 35,100 shares worth $8.11M.
  • Bellevue Group added most to Stryker in Q2 2016, an estimated $5.81M increase.
  • Bellevue Group's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $6.82M.
  • Bellevue Group fully exited Insys Therapeutics, Inc. in Q2 2016, selling an estimated $4.49M.
  • Bellevue Group's ten largest holdings make up 30% of its $531M portfolio in Q2 2016.
  • Bellevue Group opened 9 new positions and closed 15 in Q2 2016.
  • Bellevue Group's portfolio value fell 3.6% quarter-over-quarter to $531M.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.